Magdalena Fidelis

Magdalena Fidelis

Auto-generated profile, based on publicly available information

Magdalena Fidelis

Szpital Morski Im. PCK, Gdynia, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
MCMaksymilian Czarnota
Maksymilian Czarnota
MWMaria Wojcieszek
Maria Wojcieszek
DGDominika Gacka
Dominika Gacka
AŻAleksandra Żołnierek
Aleksandra Żołnierek
KGKatarzyna Gondek
Katarzyna Gondek
ZTZuzanna Tanç
Zuzanna Tanç
Thyroid health is intricately linked to nutritional status, as multiple micronutrients and dietary components modulate hormone biosynthesis, metabolism, and immune function. The increasing global prevalence of autoimmune thyroid disorders, particularly Hashimoto’s thyroiditis and Graves’ disease, underscores the need to examine the influence of modifiable dietary factors on thyroid pathophysiology. This narrative review aimed to evaluate current evidence on the role of nutrition—especially micronutrients such as iodine, selenium, iron, zinc, and vitamin D—in thyroid function and autoimmunity. A structured literature search was conducted using PubMed and Scopus to identify relevant human studies published between January 2002 and March 2025. A total of forty-one peer-reviewed articles were selected based on predefined inclusion criteria and assessed for scientific rigor and relevance. The evidence confirms the critical involvement of iodine and selenium in thyroid hormone synthesis and immune modulation, while iron and zinc were found to support enzymatic activity and endocrine stability. Vitamin D emerged as a potential immunoregulatory agent in autoimmune thyroid disease. Furthermore, certain macronutrients—including high-quality proteins, fiber, and omega-3 fatty acids—as well as dietary patterns such as the Mediterranean diet, were associated with favorable thyroid outcomes. Conversely, the intake of goitrogenic foods and soy isoflavones may necessitate caution in predisposed individuals. These findings highlight the relevance of individualized, evidence-based nutritional strategies as adjunctive approaches in the prevention and clinical management of thyroid disorders.

30 June 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
KGKatarzyna Gondek
Katarzyna Gondek
MWMaria Wojcieszek
Maria Wojcieszek
MCMaksymilian Czarnota
Maksymilian Czarnota
DGDominika Gacka
Dominika Gacka
MFMagdalena Fidelis
Magdalena Fidelis
ZTZuzanna Tanç
Zuzanna Tanç
Down syndrome (DS), or trisomy 21, is the most common chromosomal disorder, characterized by intellectual disability, congenital anomalies, and an increased risk of neurodegenerative diseases. This review synthesizes current knowledge on the etiology, clinical presentation, and modern therapeutic strategies for DS, including early intervention, medical management, and psychosocial support. Particular emphasis is placed on the revolutionary potential of CRISPR-Cas gene-editing technology as a tool for future treatment strategies. Drawing upon findings from many scientific publications, the article discusses the mechanism of CRISPR, its current medical applications, and its experimental use in silencing the extra chromosome 21 or correcting DS-associated genes. Technical, ethical, and delivery-related limitations are explored, alongside speculative but promising research directions, including base editing, prime editing, and cerebral organoids. The article concludes with a reflection on whether societal perceptions of genetic diversity should evolve alongside scientific innovation, highlighting that the greatest breakthrough may come not from altering genomes, but from fostering inclusion and understanding.

6 July 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
ZTZuzanna Tanç
Zuzanna Tanç
PKPaulina Kędziorek
Paulina Kędziorek
NANoor Al-Karawi
Noor Al-Karawi
MCMaksymilian Czarnota
Maksymilian Czarnota
MWMaria Wojcieszek
Maria Wojcieszek
WSWiktoria Szumlińska
Wiktoria Szumlińska
Postpartum psychosis (PPP) is a rare but severe psychiatric condition that typically emerges within the first two weeks after childbirth, requiring immediate clinical intervention due to risks of suicide and infanticide. Despite its severity, PPP remains under-recognized in major diagnostic classifications such as the DSM-5 and ICD-10, complicating diagnosis and legal considerations. This review synthesizes current knowledge on PPP, including its epidemiology, multifactorial etiology, clinical presentation, and management strategies. Risk factors span genetic vulnerability, hormonal and immune dysregulation, sleep disruption, and psychosocial stressors. Diagnosis is often delayed due to stigma and lack of specific screening tools. Treatment includes a stepwise pharmacological approach using benzodiazepines, antipsychotics, lithium, and electroconvulsive therapy (ECT) for refractory cases, alongside psychosocial interventions. Lithium maintenance therapy has demonstrated significant efficacy in relapse prevention, while medication safety during lactation remains a key clinical concern. The review underscores the urgent need for standardized diagnostic criteria, greater public and professional awareness, and further research into the biological mechanisms underlying PPP. Timely detection and coordinated care can significantly improve outcomes for both mother and child.

6 July 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
DGDominika Gacka
Dominika Gacka
MCMaksymilian Czarnota
Maksymilian Czarnota
MWMaria Wojcieszek
Maria Wojcieszek
AŻAleksandra Żołnierek
Aleksandra Żołnierek
KGKatarzyna Gondek
Katarzyna Gondek
ZTZuzanna Tanç
Zuzanna Tanç
The reclassification of Asperger’s syndrome within DSM-5 (2013) and ICD-11 (2019) marked a pivotal moment in the diagnostic landscape of neurodevelopmental disorders. After three decades of being recognized as a distinct clinical entity, Asperger’s syndrome was merged into the broader autism spectrum disorder (ASD) category, triggering extensive debate over diagnostic precision, social identity, and clinical consequences. This review synthesizes evidence on the evolution of diagnostic criteria, with a focus on historical milestones (Kanner, Asperger, Wing) that shaped the conceptualization of autism and Asperger’s syndrome across successive DSM and ICD editions. A structured literature search (PubMed, Scopus, Google Scholar; 2005–2024) identified 92 peer-reviewed articles meeting inclusion criteria (English or Polish language, human studies, and clear reference to diagnostic transitions and their psychosocial or clinical impact). Special attention is given to the effects of reclassification on individuals’ identity, the risk of diagnostic loss—especially in those with mild or atypical profiles—and the evolving terminology debate. Findings indicate that approximately 10–15% of individuals previously diagnosed with Asperger’s syndrome no longer meet ASD criteria under DSM-5 and ICD-11, raising concerns about service access and psychological well-being. The review also discusses challenges in distinguishing ASD from personality disorders, the diagnostic implications of camouflaging behaviors, and future research directions aimed at refining assessment tools and supporting neurodivergent identity.

6 January 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
MFMagdalena Fidelis
Magdalena Fidelis
MWMaria Wojcieszek
Maria Wojcieszek
KGKatarzyna Gondek
Katarzyna Gondek
DGDominika Gacka
Dominika Gacka
AZAgnieszka Zalewska
Agnieszka Zalewska
ZTZuzanna Tanç
Zuzanna Tanç
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have advanced from incretin-based therapies for type 2 diabetes to multifaceted treatments addressing obesity, cardiovascular disease, and emerging neuropsychiatric conditions. This review examines their physiological mechanisms, pharmacological profiles, and clinical outcomes based on data through early 2026. GLP-1 RAs mimic the incretin effect, enhancing insulin secretion, delaying gastric emptying, and modulating central reward pathways in the mesolimbic system. Approved agents like semaglutide and tirzepatide achieve 15-25% weight loss, reduce major adverse cardiovascular events by 12-26%, and show promise in heart failure with preserved ejection fraction and chronic kidney disease. Recent trials indicate potential in alcohol use disorder, with semaglutide reducing heavy drinking and cravings, though cognitive benefits in major depressive disorder remain unproven. Safety analyses from large cohorts (2024-2025) confirm no increased thyroid cancer risk (HR 0.81-0.93), and FDA reviews (2026) find no causal suicidality link. Overall, GLP-1 RAs bridge metabolic and behavioral health, supporting a unified view of energy regulation. Ongoing research on patient responders and targeted analogues will guide their integration into care for metabolic psychiatry, emphasizing balanced risk assessment.

6 January 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
MFMagdalena Fidelis
Magdalena Fidelis
MWMaria Wojcieszek
Maria Wojcieszek
KGKatarzyna Gondek
Katarzyna Gondek
DGDominika Gacka
Dominika Gacka
AZAgnieszka Zalewska
Agnieszka Zalewska
ZTZuzanna Tanç
Zuzanna Tanç
Ryanodine receptor 1-related myopathies (RYR1-RM) constitute the most prevalent class of non-dystrophic congenital myopathies, representing a complex intersection of genetic heterogeneity, molecular pathology, and evolving therapeutic paradigms. Characterized by mutations in the RYR1 gene, these disorders manifest across a broad clinical spectrum ranging from static congenital weakness to life-threatening pharmacogenetic traits such as Malignant Hyperthermia Susceptibility (MHS). This review article provides an exhaustive synthesis of the scientific and societal landscape of RYR1-RM as of 2025. We provide a deep mechanistic analysis of the RyR1 channel's structure-function relationship, elucidated through recent cryo-electron microscopy breakthroughs that define the "leaky channel" pathophysiology. We critically evaluate the emerging pharmacological arsenal, including the landmark Phase 1b trial of the Rycal compound ARM210 (S48168), the novel application of epigenetic modulation via 5-aza-2'-deoxycytidine, and the repurposed utility of dantrolene and salbutamol. Furthermore, we dissect the frontier of precision genetic engineering, detailing the mechanics and efficacy of Prime Editing and Twin Prime Editing strategies, alongside the development of myotropic viral vectors (MyoAAV) designed to overcome the delivery barriers inherent to the massive RYR1 gene. Beyond the bench, this report integrates a rigorous social science perspective, analyzing the health economic frameworks (ICER, QALYs) that govern access to orphan drugs, the ethical dimensions of somatic gene editing for non-lethal disabilities, and the transformative role of patient advocacy in the rare disease ecosystem. This multidimensional review aims to serve as a foundational resource for clinicians, researchers, and policymakers navigating the complex transition from supportive care to disease-modifying precision medicine.